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ABSTRACT
Pharmacological inhibitors of glycogen synthase kinase 3 (GSK3) and p38 mitogen-activated protein kinase (p38 MAPK),
two kinases commonly associated with signaling within cells, have been shown to suppress in vivo or ex vivo growth of
plasmodial sp. Here we evaluated antiplasmodial activities ex vivo of four inhibitors against GSK3 [lithium chloride (LiCl),
kenpaullone, (2’Z, 3’E)-6-bromoindirubin-3’-oxime (BIO) and SB216763]; and two against p38 MAPK (RWJ67657 and
SB202190) individually and in combination preparatory to understanding the role of protein kinases in plasmodial development.
The order of decreasing growth-suppressing potencies of the GSK3 inhibitors tested against Plasmodium falciparum 3D7
cultured ex vivo in erythrocytes was BIO (IC50=3.13 μM) > kenpaullone (IC50 = 18.3 μM) > SB216763 (IC50= 27.12 μM)
> LiCl (IC50= 25 468 μM). The p38 MAPK inhibitor, RWJ67657, displayed an IC50 of 7.52 μM against 3D7. SB202190
was less effective at inhibiting 3D7 displaying an IC50 of 14.80 μM. When tested in combination, marked synergism was
observed for combination of BIO or SB216763 with RWJ67657. In conclusion, GSK3 and MAPK inhibitors showed potent
antiplasmodial activities. Synergistic effects observed between BIO or SB216763 and RWJ67657 in inhibiting plasmodial
growth may implicate interaction between MAPK and GSK3 pathways and warrant further investigation.
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INTRODUCTION
Malaria remains a major human disease today with
3300 million people at risk of infection in 2010
despite serious strategies to eradicate the disease.
Approximately 90% of malaria-related deaths in
sub-Saharan Africa occur essentially among children
below the age of five (WHO, 2012). Plasmodium
falciparum is one of four Plasmodium species
affecting humans and the most deadly. Rapid
development of parasite resistance towards available
antimalarial drugs (chloroquine, mefloquine,
quinine, pyrimethamine, artemisinin) presents a
significant challenge to prevention and elimination
efforts for the disease (Winstanley, 2000). This has
escalated research for novel drug targets of which
protein kinases have attracted wide attention (Doerig
2004).
Protein kinases represent attractive candidates
as drug targets in diseases with dysfunctional
phosphorylation activities. Gleevec, a drug
introduced for the treatment of leukemia, bone
marrow disorders and skin cancer was the first
protein kinase inhibitor to have been
commercialized (Cohen 2002). Because of their
essential roles in crucial cellular functions in
eukaryotes, protein kinases are also attractive
potential targets for drugs against eukaryotic
infectious agents such as plasmodium and
trypanosomatids. In malarial infections, inhibitors
of glycogen synthase kinase 3 (GSK3) and mitogen-
activated protein kinase (MAPK), two protein
kinases with essential roles in the plasmodial life
cycle, have been reported to individually suppress
development of plasmodial sp. (Drocheau et al.,
2004, Brumlik et al., 2011).
GSK3 is a serine/threonine kinase first
discovered in 1980 for its role in glycogen
metabolism (Embi et al., 1980). More than forty
substrates phosphorylated by GSK3 have since been
identified thus illustrating the capability of GSK3
to affect diverse cellular processes from glycogen
and protein synthesis, to the regulation of
transcription factors, embryonic development, cell
proliferation and adhesion, tumorigenesis, apoptosis
and neuronal death (Doble & Woodgett, 2003).
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The mitogen-activated protein kinase (MAPK)
pathway, a three-tiered cascade of phosphorylation-
dephosphorylation found in all eukaryotes, is a vital
mediator of a number of cellular fates including
growth, proliferation, survival, apoptosis,
inflammation and cell death (Chen et al., 2001,
Hommes et al., 2003). There are three major
distinctly-regulated groups of MAPK cascades
known in humans; extracellular regulated protein
kinase ½ (ERK½), c-Jun NH2 terminal kinase (JNK)
and p38 MAPK. MAPK cascades play a central
role in progression of Alzheimer’s disease, cancer
development, neuro-inflammatory responses as well
as neuronal death in Parkinson’s disease (Kim &
Choi 2010).
Knowledge on molecular mechanisms involved
in combination therapies may provide clues in
understanding pathways with specific mechanisms
of action. Both GSK3 (Meijer et al., 2004) and
MAPK (Lawrence et al., 2008), which are known
to mediate normal signaling in multiple cellular
processes, are implicated in the pathogenesis of
malaria. Interestingly, it has been reported that direct
phosphorylation by p38 MAPK may inactivate
GSK3β activity (Thornton et al., 2008). Here we set
out to investigate if pathways involving GSK3 and
MAPK may interact to cause suppression of
plasmodial growth.
MATERIALS AND METHODS
P. falciparum cultivation and maintenance
3D7, a chloroquine-sensitive P. falciparum
strain, obtained from the Malaria Research and
Reference Reagent Resource Centre (MR4,
Manassas, Virginia) was grown and maintained in
culture at 1% hematocrit of purified O+ human
erythrocytes in RPMI 1640 media supplemented
with 0.5% Albumax II (GIBCO, Life Technologies,
USA), 25 mM HEPES, 100 μM hypoxanthine, 12.5
μg/mL gentamicin and 1.77 mM sodium
bicarbonate at 37°C, 5% CO2 (Radfar et al., 2009).
The parasitemia level was evaluated by microscopic
inspection of Field-stained thin smears.
Drug and inhibitors
Chloroquine diphosphate was purchased from
Sigma Chemical Company (USA). The GSK3
inhibitor, lithium chloride was purchased from
Fluka (USA), kenpaullone and SB216763 were
obtained from Merck (Germany), and (2’Z,3’E)-6-
bromoindirubin-3’-oxime (BIO) from Sigma
Chemical Company (USA). The p38 MAPK
inhibitors RWJ67657 and SB202190 were
purchased from Tocris Bioscience (USA).
Determination of inhibitor susceptibility in vitro
Susceptibility of the 3D7 strain of P. falciparum
to various inhibitors was measured using WHO
microtest and parasite lactate dehydrogenase (pLDH)
assays. Parasite LDH assays were performed
according to Makler et al. (1993) in flat-bottomed
96-well microtiter plates. Unparasitized O+
erythrocytes without inhibitors were used as blanks
for the assay; and parasitized erythrocytes without
inhibitors served as controls for the assay. Parasites
were plated in the 90% ring phase at 1% hematocrit
and 2% parasitemia in 100 μL of inhibitors at
defined concentrations. Plates were placed in the
CO2 incubator and incubated for 48 hours. When
incubation was complete, the plates were subjected
to three 20 minute freeze-thaw cycles. Thereafter,
100 μL Malstat reagent (0.2% (v/v) Triton X-100,
0.02 g/mL L-lactate, 6.6 mg/mL Tris buffer, 0.11 mg/
mL 3-acetylpyridine adenine dinucleotide (APAD),
pH 9 and 25 μL NBT/PES solution (1.6 mg/mL nitro
blue tetrazolium, 0.08 mg/mL phenazine ethosulfate)
were added to each well of fresh 96-well microtiter
plates. Culture (15 μL) was taken from each well and
added to the corresponding well of the Malstat
plates. Color development in the plates were
monitored at 620 nm using a microplate reader
(Fluostar Optima) after an hour of incubation at
room temperature in the dark. Data were analyzed
using GraphPad Prism 5 (GraphPad Software, Inc.,
San Diego, CA) by non-linear regression to yield
50% inhibitory concentrations (IC50).
Stage-specific developmental inhibition
Highly synchronized parasite ring stage cultures
obtained by D-sorbitol treatment (Radfar et al.,
2009) at 2% parasitemia and 5% hematocrit, were
exposed to GSK3 or p38 MAPK inhibitors using
concentrations required to achieve 90% growth
inhibition as obtained earlier from the inhibitor
susceptibility (pLDH) assay (Skinner et al., 1997).
Drug or inhibitor exposure studies were performed
at 0 hour (ring stage), 28 hour (trophozoite stage),
42 hour (schizont) and 54 hour (ring). Purity of
individual stages was confirmed to be greater than
95% by light microscopic examination of field-
stained thin smears of the cultures (Dobson et al.,
2001).
Ex vivo inhibitor combination bioassay
Method described by Canfield et al. (1995) was
adopted. Briefly, every fixed ratio of predetermined
concentrations needed to inhibit parasite growth by
50% (IC50) was used to determine the interaction of
two inhibitors. Initial concentrations 20-50 times
the estimated IC50 values combined in nine
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combination ratios of 90:10 to 10:90 (inhibitor A:
inhibitor B) of three GSK3 inhibitors and RWJ67657
were tested against P. falciparum 3D7 (Kebeneil et
al., 2004). Highest concentrations of each inhibitor
were prepared to allow the IC50 of the individual
inhibitor to fall around the midpoint in a two-fold
serial dilution. Combined inhibitors were dispensed
into the 96-well microtiter plates and subsequent
procedures were followed as described in the
determination of inhibitor susceptibility in vitro
described above.
The degree of synergy was evaluated according
to the method of Berenbaum et al. (1978). Fraction
inhibition concentration (sum FIC) was calculated
using the formula:
Ac/Ae + Bc/Be = K (sum FIC)
where Ac and Bc are the equally effective
concentrations (IC50) when used in combination,
and Ae and Be are the equally effective
concentrations when used alone. FICs < 1 indicates
synergism, sum FICs > 1and < 2 indicates additive
interaction and sum FIC > 1 indicates antagonism
(Gupta et al., 2002).
RESULTS
GSK3 and p38 MAPK inhibitors individually
suppressed P. falciparum growth
We first evaluated effects of a panel of GSK3
and p38 MAPK inhibitors (lithium chloride,
kenpaullone, BIO, SB216763, RWJ67657 and
SB202190) individually on growth of P. falciparum
3D7 in culture. The 50% inhibition concentrations
for each inhibitor tested are shown in Table 1. Of
the GSK3 inhibitors examined, BIO exhibited the
most potent GSK3 inhibitory effect on growth of the
chloroquine-sensitive 3D7 parasite strain with an
IC50 of 3.13 μM (Table 1). The order of decreasing
inhibitory activity for the GSK3 inhibitors tested is
BIO > kenpaullone > SB216763 > lithium chloride.
As for p38 MAPK inhibitors tested, RWJ67657
showed more effective inhibition compared to
SB202190 displaying IC50 values of 7.52 μM and
14.80 μM respectively.
GSK3 and p38 MAPK inhibitors arrested
plasmodial ring-trophozoite transition stage
Next we examined the 3D7 parasite
developmental stage affected by the GSK3 and p38
MAPK inhibitors. Comparisons between Giemsa-
Fig. 1. Normalized isobolograms showing the interaction between GSK3 inhibitors; lithium chloride, SB216763 and BIO
with RWJ67657 against P. falciparum 3D7 strain.
Table 1. In vitro anti-plasmodial activity
Drug/Inhibitor Antiplasmodial activity IC90  (µM)(P. falciparum 3D7), IC50 (µM)
GSK3 Lithium Chloride 25 468 ± 1.109 213 796
Kenpaullone 18.30 ± 1.202 169.8
BIO 3.13 ± 1.249 11.22
SB216763 27.12 ± 0.0013 93.3
p38 MAPK RWJ 67657 7.52 ± 1.285 66
SB202190 14.8 ± 1.286 100
Control Chloroquine 0.0084 ± 0.0011 0.063
68 SYNERGISTIC EFFECTS OF GSK3 AND p38 OF Plasmodium falciparum EX VIVO
Fig. 2. Morphological changes in parasites observed after incubation with GSK3 and p38 MAPK inhibitors. Highly
synchronous P. falciparum 3D7 cultures were exposed to Lithium chloride (213 mM), Kenpaullone (170 μM), BIO (11
μM), SB216763 (93 μM), RWJ67657 (66 μM), SB202190 (100 μM) and Chloroquine (0.063 μM).
stained thin blood smears prepared from the parasite
cultures treated with the inhibitors against non-
treated controls revealed that control non-treated
cultures completed their intra-erythrocytic
development within the asexual cycle. This was
deduced from the presence of ring, trophozoite,
schizont, and ring morphologies as observed under
the microscope in cultures obtained at the 0, 28, 42
and 54 hour time-points respectively (Figure 2). In
contrast, only ring stage parasites were observed in
cultures treated with inhibitors within the same
time-points. We also observed that developmental
retardation yielded trophozoites that were
diminished in size with lesser pigment colour
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Table 2. Sum FICs for the interactions of GSK3 inhibitors – RWJ67657 against 3D7 P. falciparum
Inhibitor combination
            Fixed combination ratio (Mean of FIC50)
90:10 80:20 70:30 60:40 50:50 40:60 30:70 20:80 10:90
Lithium chloride + RWJ67657 1.841 2.01 2.282 2.425 2.021 0.943 1.059 0.993 0.839
SB216763 + RWJ67657 0.929 0.876 0.929 0.923 0.819 0.806 0.843 0.908 0.732
BIO + RWJ67657 0.554 0.822 0.790 0.904 0.857 0.953 0.798 0.777 0.788
starting at 28 hours of culture in the presence of all
tested inhibitors (Figure 2). The latter observation
is indicative of successful inhibition of parasite
developmental stage by the GSK3 and p38 MAPK
inhibitors. The results obtained strongly suggest
that GSK3 and p38 MAPK inhibitors caused stage-
specific growth inhibition specifically suppressing
conversion of ring to trophozoite morphologies.
More profound inhibition on growth of P.
falciparum was observed with combination of
inhibitors
The antiplasmodial activities of GSK3
inhibitors (lithium chloride, SB216763 and BIO) in
combination with RWJ67657 were investigated
against 3D7 P. falciparum culture. The mean sums
of the fractional inhibitory concentration (FIC) for
each fixed ratio of each combination are summarized
in Table 2. The sum FIC values obtained were then
used to construct isobolograms (Figure 1).
Interaction of lithium chloride with RWJ67657
The mean sums of FIC values of the interaction
of lithium chloride with RWJ67657 are shown in
Table 2. The isobologram for the interaction of
lithium chloride with RWJ67657 (Figure 1A) tended
towards antagonism at all ratios tested except for
ratio 20:80 and 10:90 with mean range sums of FIC
of 1.841 (0.839-2.425).
Interaction of SB216763 and BIO with RWJ67657
The isobolograms for the interactions between
SB216763 and BIO with RWJ67657 are presented
in Figures 1B and 1C, and the mean sums of FIC
values are presented in Table 2. The interactions
against 3D7 strain from both combinations were
synergistic. The mean range sums of FIC values of
SB216763 and BIO with RWJ67657 against 3D7
cultures obtained were 0.876 (0.732-0.929) and
0.798 (0.554-0.953) respectively.
DISCUSSION
The current study is an investigation on the
individual ex vivo antiplasmodial activities of a
panel of GSK3 inhibitors (LiCl, kenpaullone, BIO
and SB216763); and two p38 MAPK inhibitors
(RWJ67657 and SB202190) against chloroquine-
sensitive 3D7 strain of P. falciparum. Three of these
GSK3 inhibitors, LiCl, BIO and SB216763 were then
selected based on variations in their GSK3-
inhibitory mechanisms for combination experiments
against 3D7 with the more potent antiplasmodial
p38 MAPK inhibitor, RWJ67657. The present study
is an effort to elucidate the role of GSK3 and MAPK
signaling during malarial parasite development.
Both GSK3 and p38 MAPK inhibitors tested
individually showed potent inhibitory activities on
replication of P. falciparum 3D7 cultured ex vivo
in erythrocytes. This concur with previous reports
on the effects of kinase inhibitors on P. falciparum
i.e. inhibition of recombinant P. falciparum GSK3
by GSK3 inhibitors (Drocheau et al., 2004) and
antiplasmodial activities of MAPK inhibitors
against P. falciparum in culture (Brumlik et al.,
2011). We have also previously demonstrated
chemo-suppressive effects of LiCl on P. berghei
development in a murine model of malarial
infection (Nurul Aiezzah et al., 2010).
Among apicomplexan parasites, the essential
roles of GSK3 and MAPK in parasite development
as implicated from inhibitor studies described
above, are not limited to the plasmodial sp. In
human African trypanosomiasis, a short protein
isoform of Trypanosoma brucei GSK3 was shown to
be essential for parasite growth and viability (Ojo
et al., 2008). Also Xingi et al. (2009) provided
evidence that Leishmania donovani GSK3 was
involved in cell-cycle control and pathways leading
to apoptosis-like death. Additionally, Wei et al.
(2002) and Pfister et al. (2006) reported direct
involvement of p38 MAPK in the developmental
stages of Toxoplasma gondii and Trypanosoma
brucei respectively.
Noteworthy, findings from the present study
revealed that ATP-competitive and more specific
pharmacological inhibitors of GSK3 (kenpaullone,
BIO and SB216763) were more potent at suppressing
growth of P. falciparum 3D7 compared to the non-
ATP-competitive GSK3 inhibitor, LiCl. All GSK3
and MAPK inhibitors tested, however arrested the
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trophozoite stage of P. falciparum growth thus
possibly implicating similar targets for both kinases
in parasite development.
When tested in combination with the MAPK
inhibitor, RWJ67657 against the 3D7 parasite strain,
BIO and SB216763 each displayed synergistic
interactions with more profound inhibitory
effects on parasite growth. In contrast, LiCl-
RWJ67657 combination resulted in an antagonistic
relationship. In other words, LiCl exhibited less
favorable inhibition with a higher IC50 on parasite
growth upon combination with the p38 MAPK
inhibitor.
As BIO and SB216763 are two ATP-competitive
inhibitors which both negatively affect
phosphorylation of Tyr 216 in GSK3 (Meijer et al.,
2003; Schutz et al., 2011), it is tempting to suggest
that the enhanced antiplasmodial actions seen
here with these inhibitors when combined with
RWJ67657 may be attributed in part to their effects
on the tyrosine phosphorylation. The results shown
here is in agreement with Drocheau et al. (2004)
who reported that residues thought to be involved
in the activation of GSK3 through tyrosine
phosphorylation are conserved in P. falciparum.
LiCl, in contrast is a non-ATP-competitive inhibitor
in which inhibition of GSK3 is by direct competition
with magnesium ions; or indirectly via enhanced
serine phosphorylation and autoregulation (Klein &
Melton 1996; Kirshennboim et al., 2004).
Upstream signaling pathways mediated by
MAPKs reported to eventually lead to GSK3
inhibition include a pathway which involves
phosphorylation of a serine residue by a MAPK-
activated protein kinase (Cohen & Frame, 2001). In
addition, Ding et al. (2005) reported that active
ERK2 phosphorylated a Thr 43 residue in human
GSK3β. p38 MAPK has also been reported to
specifically phosphorylate GSK3â at residue Thr
390 (Thornton et al., 2008).
Based on our findings described here, both
combinations of SB216763 and BIO with
RWJ67657 showed greater inhibition compared to
their individual effects implying that GSK3 and
MAPK have coordinated actions. This synergistic
interaction suggests that combined inhibition of
GSK3 and MAPK is a plausible approach for
development of a more potent antimalarial drug.
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